Calithera Biosciences Inc (CALA.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2010||President, Chief Executive Officer, Co-Founder, Director|
|46||2016||Senior Vice President - Business and Corporate Development|
|63||2013||Senior Vice President - Development|
|45||2015||Senior Vice President, Clinical Development|
|60||2010||Senior Vice President - Drug Discovery|
- BRIEF-Calithera Biosciences Q1 Loss Per Share $0.37
- BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma
- BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln
- BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018